Tanox to Report Promising Results for AIDS Drug
October 26, 2005
The Houston-based biotechnology firm Tanox Inc. is expected today to report encouraging results from an ongoing Phase II safety and efficacy study of its intravenous HIV entry inhibitor drug TXN-355.
Designed to block entry into human cells by both X4 and R5 classes of HIV, TXN-355 lowered HIV levels in blood better than a placebo in 82 patients in the trial, with only mild adverse drug reactions reported so far, said Tanox. Patients in both control and TXN-355 groups also received a standard AIDS drug cocktail.
TXN-355 is created from the natural infection-fighting monoclonal antibodies of mice; these are genetically engineered to lose their mouse qualities and behave like human antibodies. R5 and X4 viruses use different portals to enter cells; Tanox said the dual-class blocking TXN-355 represents "a major advantage" over drugs that block HIV from infecting cells through one portal only.
Granted fast-track status by the Food and Drug Administration, TXN-355 could be used for a broad class of HIV patients, including those with HIV resistant to multiple drugs, said Stanley Lewis, Tanox medical director. After completion of the current trial, Tanox plans to begin a final Phase III study next year, said Lewis, adding that the drug could be on the market as early as 2009.
Wall Street Journal
10.26.05; Marilyn Chase
Senate Rejects Coburn Spending Bill Amendment to Transfer $60 Million From CDC Construction, Renovation Project to ADAP
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.